A Study of Dapsone Gel in Females With Skin of Color and Acne Vulgaris

Allergan

Status and phase: Completed; Phase 4

Conditions: Acne Vulgaris

Treatments: Drug: Dapsone Gel

Study type: Interventional

Funder types: Industry

Identifiers

NCT02032407

GMA-ACZ-13-001

Details and patient eligibility

About

This study will evaluate the effect of dapsone gel in female subjects with skin of color (Fitzpatrick Skin Types IV, V, and VI) with acne vulgaris.

Enrollment: 68 patients

Sex: Female

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Diagnosis of acne vulgaris
• Medium to dark complexion (Fitzpatrick Skin Type IV, V or VI)
• Willing to avoid excessive or prolonged exposure of the face to ultraviolet light (eg, sunlight, tanning beds) throughout the study

Exclusion criteria

• Received treatment with botulinum toxin of any serotype in the face within 6 months

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

68 participants in 1 patient group

Dapsone Gel

Experimental group

Description:

Dapsone Gel (Aczone®) applied twice daily to the face for 12 weeks.

Treatment:

Drug: Dapsone Gel